Resistant hypertension, defined as failure to achieve goal blood pressures in patients taking optimal or maximum tolerated doses of three or more antihypertensive drugs, is estimated to occur in about 25% of hypertensive patients on treatment. Poor adherence with treatment is considered to have an important role leading to apparent drug resistant hypertension. We have demonstrated that observed drug taking ('tablet feed'), followed by close monitoring of blood pressure in a clinic environment, together with ambulatory blood pressure monitoring, identifies a high proportion of patients (about two-thirds) of those presenting with resistant hypertension, whose persistently elevated blood pressure levels are due to poor adherence with drug treatment.
High blood pressure remains the major risk factor contributing to the global burden of disease. 1 Population surveys consistently report that those receiving antihypertensive treatment are, in general, poorly controlled. 2 In the United Kingdom, for example, only about one-half of hypertensive patients on treatment achieve target blood pressures (o140/90). 3 'Resistant hypertension' has been a loosely worded term to categorize hypertensive patients whose blood pressure has failed to reach target levels despite antihypertensive drug use, and is a major cause of referral to specialist centres. Resistant hypertension represents a heterogeneous group of patients, which includes: patients on inadequate doses and/or insufficient number of drugs, poor patient adherence with treatment (also known as pseudo-resistant hypertension), white coat hypertension, undiagnosed secondary hypertension and true resistant hypertension. The prevalence of true resistant hypertension, currently defined as failure to achieve target blood pressures despite the use of three or more medications at optimal or maximum tolerated doses, is not known, but estimated to occur in about 25% of hypertensive patients receiving treatment. 4 However, the proportion of these 'true' resistant hypertensive patients is likely to include an unknown number of patients with pseudo-resistant hypertension. In either case, such patients are at high residual cardiovascular risk because of poor blood pressure control.
To provide further insight into patients with suspected true resistant hypertension, we assessed 37 patients who had been referred to a specialist hypertension centre with uncontrolled hypertension and whose blood pressures had remained uncontrolled on three or more drugs at frequent clinic assessments, despite drug and dose adjustment. Underlying causes of secondary hypertension had been excluded, and all patients stated that they were adherent with their prescribed medications.
Methods
Patients were referred to a specialist nurse-led clinic where drugs were administered under observation and the patients followed for a period of up to 30 h.
Patients were told to omit their morning medications and to arrive in the clinic between 9 and 10 am. Blood pressures were recorded by a standardised technique using an independently validated automated monitor, following which drugs were administered orally. Blood pressures were recorded at 10-15 min intervals for 2-4 h. In patients on three or more drugs the initial administration consisted of giving two of their prescribed drugs (usually a calcium channel blocker and an angiotensin converting enzyme inhibitor or angiotensin receptor blocker), with the additional medications (diuretics, b-blockers, a-blockers and so on) administered at appropriate intervals over the ensuing 2-4 h depending on blood pressure responses. Following a severe hypotensive response to the a-blocker, doxazosin, in one of the patients studied early in the series, we proposed that for patients prescribed higher doses of doxazosin, a maximum dose of 4 mg of the longer acting XL formulation should be administered in the context of the tablet feed. At the end of the observation period, of the initial 37 patients, 28 were fitted with an ambulatory monitoring blood pressure (ABPM) device (Spacelabs 90217, Dolby & Co., Sterling, Scotland) and were asked to return the following day to complete the blood pressure assessment.
Results
Subjects were of average age 57 (range 20-87) and 65% were female. They were of varied ethnicity ( Table 1 ). The average number of antihypertensive drugs used was 5 (range 3-7). At the time of referral, median clinic blood pressures were systolic blood pressure (SBP) 179 mm Hg, diastolic blood pressure 98 mm Hg (Table 2) . These values fell to SBP 156 mm Hg, diastolic blood pressure 86 mm Hg, by the morning of the tablet feed and to SBP 144 mm Hg, diastolic blood pressure 83 mm Hg at the end of the initial observation period (Figure 1 ). Of the initial 37 patients, SBP control (o140 mm Hg) was achieved in 16 patients and diastolic pressure control (o90 mm Hg) in 26 patients. Systolic and diastolic control was achieved in 15 patients.
The results of the ABPM study demonstrated that daytime median pressures were, on average, 139/80, 8/5 mm Hg lower than the blood pressures recorded at the end of the initial observation period following drug administration. White coat hypertension, arbitrarily defined as a difference between clinic pressure and daytime mean pressure on ABPM of 420 mm Hg SBP was observed in five patients. Subsequently patients were either followed up by the nurse specialist or returned to their referring physician with a recommendation for counselling with regard to the importance of adherence with drug treatment where this was thought to be appropriate. In some cases, particularly in older patients on multiple drug therapies, including those for comorbidities, the use of a multi-compartment pill box or 'dosset' box was found to be particularly helpful.
In addition to those patients controlled by the end of the period of observation, a further seven patients, at their most recent clinic follow up visit, had achieved blood pressures of o140/90 mm Hg (Figure 1 ). True resistant hypertension in this small series, therefore, accounted for only 15 patients, or about 40% of those originally referred. For the goal of o150/90 (the United Kingdom audit standard) this represented eight patients or about one-fifth (22%) of those originally referred. It is evident from blood pressures recorded at the most recent clinic visit that many patients controlled during the tablet feed had blood pressures that rose to pre-investigation levels, which we again interpret as a return to non-adherence.
Of the 34 patients followed up for a further 1-18 months, at their most recent clinic visit, about half (15) had drug(s) and/or dose(s) reduced. Of these, six patients had three or more drugs stopped, approximately one-third (11) needed no change in their medicines, five needed an increase in dose and two needed an additional drug.
Discussion
High blood pressure places a substantial economic burden on health care resources and is estimated to cost the United Kingdom around d10 billion each year. Poorly controlled blood pressure contributes significantly to these costs as benefits of antihypertensive treatment rely on good blood pressure control. The present survey attempted to evaluate the contributing causes of resistant hypertension, albeit in a small sample of patients attending a specialist clinic. From these observations, it is clear that poor adherence with drug taking is a major contributing factor and one which is potentially remedial by enhanced patient involvement, assessment, support and education. 4 Evaluating adherence is not easy in the clinic. There are few clues as to whether patients are taking their tablets. Inconsistency of requests for repeat prescriptions and pill counts sometimes help. Drug assays in blood and urine are not widely available. In many suspected cases of poor adherence, patients are often not prepared to admit their failings. Of those hypertensive patients receiving three or more drugs, it is estimated that about one-quarter fail to achieve target blood pressures. 5 In the United Kingdom this represents over half a million adults of which, if our Pseudo resistant blood pressure o140/90 or o150/90 at either, the end of the tablet feed, or at most recent visit. current series is representative of the population at large, the majority can be attributed to poor adherence with treatment. The costs to the health care system of poor adherence are inestimable. In the case of hypertension, this leads to more frequent surgery attendances, referral to secondary care and specialist centres, more detailed investigations for secondary causes, hospital admission for uncontrolled blood pressure, and the costs incurred in the management of the consequences, stroke and myocardial infarction. We believe that supervised drug administration, or 'tablet feed', followed by prolonged monitoring in a clinic environment, ideally combined with ambulatory monitoring provides considerable insight into the possible causes of resistant hypertension in this subgroup of patients. Although we understand that several centres may have adopted a similar procedure for investigation of apparent drug resistant hypertension, we are unaware of any published reports. The administration of drugs should be carefully controlled and no more than two drugs given initially to avoid hypotensive episodes when more drugs are given to patients who have hitherto been poorly adherent. Particular care should be given to patients whose prescriptions included high doses of doxazosin. Although we don't have an easy solution to the problems of poor adherence with drug treatment, the information generated by the blood pressure responses to observed drug administration provides considerable insight into the underlying problem and provides an opportunity for the physician, specialist nurse and pharmacist to discuss the implications and importance of drug treatment with individual patients in the hope of achieving better blood pressure control.
